Best and brightest leukemia researchers receive $1-million from Cole Foundation

06-13-2008

For the second year in a row, the Cole Foundation is awarding $1-million in fellowships to the most promising researchers studying pediatric leukemia and related diseases. The fellowships will enable these young scientists from the Université de Montréal, McGill University and the Institut Armand-Frappier to pursue their research.

“With two major faculties of medicine and some of the best biomedical research centres in the country, Montreal is home to an amazing concentration of research talent,” explains Barry Cole, President of the Cole Foundation. “We’re proud to support the next generation of leukemia researchers to help maintain Montreal’s tradition of medical excellence. By backing the most promising talents, we hope to encourage their development. These are the people who will gradually uncover the causes of leukemia, find new ways of treating it and eventually eradicate all forms of the disease.”

Leukemia research has advanced considerably in recent years. Thirty years ago, four out of five children suffering from acute forms of leukemia would succumb to the disease. Today, research has reversed that situation: four out of five children survive but there is greater concern for secondary illnesses that develop later in life.

“We have made very heartening progress in pediatric leukemia research over the last few years, and we look forward to building on this success and erasing the illness once and for all,” notes Dr. Richard I. Levin, Vice-Principal (Health Affairs) and Dean of the Faculty of Medicine at McGill University. “The Cole Foundation provides truly outstanding support to our cause by funding the research that is taking place in Montreal today and encouraging the development of the researchers who will take this fight into the future.”

“Our universities contribute significantly to healthcare research,” said Dr. Pierre Boyle, Vice-Dean of Research and Graduate Studies of the Faculty of Medicine at the Université de Montréal. “They train most of the doctors and researchers in the country, and they are the most active in terms of research. The fellowship program established by the Cole Foundation helps us attract the best researchers to form the elite teams we need to achieve convincing results. All of these efforts come together to give patients the benefit of the best treatment and, above all, to give them hope.”

Finally, Dr. Yves St-Pierre, professor at the INRS-Institut Armand-Frappier congratulated the new Cole fellows: “They all have been selected for the exceptional quality of their work. These young researchers represent what science is at its best: dedication, passion and a constant thirst for new knowledge. We are very proud to support them in the pursuit of their work.”

The Cole Foundation research fellowship program offers $1-million over two years to be divided among 21 clinical researchers, post-doctoral researchers and students in doctoral and master’s programs. Of the 21 recipients, 15 are associated with various research laboratories at the Université de Montréal, including the Institute for Research in Immunology and Cancer (IRIC), the Sainte-Justine Research Centre, and the Hôpital Maisonneuve-Rosemont. Five fellowships will be distributed to students and researchers working at McGill University and its associated hospitals and research units, including the Royal Victoria Hospital and the Lady Davis Research Centre at the Jewish General Hospital. One fellowship is awarded to a student at the INRS-Institut Armand-Frappier.

The Cole Foundation was created in 1980 by Montreal businessman John N. (Jack) Cole to support Montreal hospitals and research in pediatric oncology and hematology. After his only child, Penny, died of leukemia, he established the Penny Cole Laboratory at the Montreal Children’s Hospital. The purpose of the lab was to foster research into the causes and potential cures for leukemia and other related diseases affecting children. In 1997, the Cole Foundation also endowed the Jack Cole Chair of Pediatric Oncology and Hematology at McGill University.

Contact:
John Moran, Cole Foundation - Office: 819.563.1716
Julie Gazaille , Université de Montréal - Office: 514.343.6796
Pascal Zamprelli, Media Relations Office - Office: 514 398-1385



Related Diseases: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML)
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Intrabone admin of unrelated cord-blood cells lets more leukemia patients undergo transplantation
Sparing leukemia patients from unnecessary chemo
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Acute Myeloid Leukemia (AML)
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Australian scientists unravel Leukaemia link
Intrabone admin of unrelated cord-blood cells lets more leukemia patients undergo transplantation
Sparing leukemia patients from unnecessary chemo
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
GlaxoSmithKline And Genmab Announce Positive Top-line Results In Ofatumumab Chronic Lymphocytic Leukaemia Pivotal Study
Sparing leukemia patients from unnecessary chemo
Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma
Chronic Myeloid Leukemia (CML)
Promyelocytic Blast Crisis of Chronic Myeloid Leukemia during Imatinib Treatment
Injection of Umbilical Cord Stem Cells into Bone Appears Promising for Leukemia
Protein key to control, growth of blood cells
Targeted therapies for CML: practical considerations and comparisons
Sparing leukemia patients from unnecessary chemo
Hodgkin Lymphoma
Nerve cancer mutations found
Autologous Stem Cell Transplantation Effective for Relapsed or Refractory Hodgkin’s Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
Multiple Myeloma
B-MS boosts biologics pipeline with PDL BioPharma deal
ESAs cut survival by more than half in multiple myeloma
How molecules out of balance lead to human multiple myeloma and other cancers
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Does a 10-year 10% Continuous Complete Remission Rate for Myeloma Patients Suggest Cure?
Myelodysplastic Syndrome (MDS)
Xanthus Presents Updated Xanafide Phase 2 Data Showing Durable Complete Remissions in Secondary AML
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
Scoring system identifies MDS patients who have low-risk disease but a poor prognosis
Seattle Genetics Initiates Phase IIb Clinical Trial of SGN-33 in Combination with Chemotherapy for Acute Myeloid Leukemia
Non-Hodgkin Lymphoma (NHL)
Nerve cancer mutations found
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
Ofatumumab Promising in Refractory Follicular Lymphoma
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
Spicy Pickle(TM) Teams With Leukemia & Lymphoma Society In 'Hike For Discovery' Fundraiser On July 18
Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer
Drug avoids radiation for early testicular cancer
Polymorphism Reduces Benefit of Bleomycin in Testicular Cancer
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer